Jacobs Levy Equity Management, Inc Mersana Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,111,998 shares of MRSN stock, worth $589,358. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,111,998
Previous 993,046
11.98%
Holding current value
$589,358
Previous $1.88 Million
15.25%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding MRSN
# of Institutions
136Shares Held
101MCall Options Held
77.2KPut Options Held
453K-
Nextech Invest Ag12.1MShares$6.4 Million3.22% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$6 Million0.76% of portfolio
-
Vr Adviser, LLC New York, NY10.3MShares$5.44 Million2.42% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$4.59 Million3.35% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$4.44 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $51.5M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...